アルツハイマー病による認知症に対するザナメム 10 mg の効果 (XanaMIA)
アルツハイマー病による軽度または中等度の認知症患者を対象としたザナメム® 10 mg 毎日の安全性、忍容性、有効性を評価するための第 2b 相、二重盲検、プラセボ対照、並行群間、36 週間、2 群試験
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究場所
-
-
California
-
Carlsbad、California、アメリカ、92011
- ACW Investigative Site 218
-
Sherman Oaks、California、アメリカ、91403
- ACW Investigative Site 209
-
-
Colorado
-
Denver、Colorado、アメリカ、80218
- ACW Investigative Site 211
-
Englewood、Colorado、アメリカ、80113
- ACW Investigative Site 208
-
-
Florida
-
Delray Beach、Florida、アメリカ、33445
- ACW Investigative Site 203
-
Miami、Florida、アメリカ、33176
- ACW Investigative site 201
-
New Port Richey、Florida、アメリカ、34652
- ACW Investigative site 202
-
Orlando、Florida、アメリカ、32803
- ACW Investigative site 204
-
The Villages、Florida、アメリカ、32162
- ACW Investigative site 205
-
-
Georgia
-
Decatur、Georgia、アメリカ、30030
- ACW Investigative Site 207
-
-
New Jersey
-
Marlton、New Jersey、アメリカ、08053
- ACW Investigative Site 206
-
-
New York
-
Albany、New York、アメリカ、12208
- ACW Investigative Site 214
-
Staten Island、New York、アメリカ、10314
- ACW Investigative Site 219
-
-
Ohio
-
Dayton、Ohio、アメリカ、45459
- ACW Investigative Site 210
-
Independence、Ohio、アメリカ、44131
- ACW Investigative Site 217
-
-
Oregon
-
Portland、Oregon、アメリカ、97225
- ACW Investigative Site 212
-
-
Rhode Island
-
East Providence、Rhode Island、アメリカ、02914
- ACW Investigative Site 216
-
-
Texas
-
Austin、Texas、アメリカ、78757
- ACW Investigative Site 220
-
-
Washington
-
Bellevue、Washington、アメリカ、98007
- ACW Investigative Site 215
-
-
-
-
New South Wales
-
Darlinghurst、New South Wales、オーストラリア
- ACW Investigative Site 106
-
Erina、New South Wales、オーストラリア
- ACW Investigative Site 103
-
Kogarah、New South Wales、オーストラリア
- ACW Investigative Site 102
-
Macquarie Park、New South Wales、オーストラリア
- ACW Investigative Site 107
-
Newcastle、New South Wales、オーストラリア
- ACW Investigative Site 111
-
-
Queensland
-
Birtinya、Queensland、オーストラリア
- ACW Investigative Site 113
-
Chermside、Queensland、オーストラリア
- ACW Investigative Site 105
-
-
South Australia
-
Bedford Park、South Australia、オーストラリア
- ACW Investigative Site 114
-
Woodville South、South Australia、オーストラリア
- ACW Investigative Site 110
-
-
Victoria
-
Carlton、Victoria、オーストラリア
- ACW Investigative Site 115
-
Ivanhoe、Victoria、オーストラリア
- ACW Investigative Site 101
-
Malvern、Victoria、オーストラリア
- ACW Investigative Site 108
-
Parkville、Victoria、オーストラリア
- ACW Investigative Site 112
-
-
Western Australia
-
Nedlands、Western Australia、オーストラリア
- ACW Investigative Site 104
-
West Perth、Western Australia、オーストラリア
- ACW Investigative Site 109
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Male or female aged 50 years or older, inclusive at the time of Screening.
-
Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria:
- Clinical Dementia Rating (CDR) global score of 0.5 to 1.0
- Mini-mental state examination (MMSE) score of 18 to 26
- Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings
- Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein.
-
If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening.
-
Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion.
-
Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.
-
Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments.
-
Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.
Exclusion Criteria:
- Use of anti-amyloid or anti-tau antibody within 6 months.
- Diagnosis of a non-AD dementia including traumatic brain injury.
- Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia.
- Participation in another clinical trial of a drug or device
- Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator.
- Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening.
- Clinical diagnosis of Type I or Type II diabetes requiring insulin.
- Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
- Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C.
- Participants with a history of clinically significant drug abuse or addiction in the past 2 years
- Evidence or history of alcohol abuse
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:10 mg Xanamem
10 mg Xanamem tablet, to be administered orally once every morning with or without food |
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
他の名前:
|
|
プラセボコンパレーター:Placebo
Placebo tablet, to be administered orally once every morning with or without food |
Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient. |
|
実験的:Open label phase
Participants enrolled in the open-label phase after the main trial will receive 10 mg Xanamem, to be administered orally once every morning with or without food |
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Effects of 10 mg Xanamem on integrated cognitive and functional abilities
時間枠:36 weeks
|
Change from Baseline to end of treatment (EOT) in the Clinical Dementia Ratio - Sum of Boxes (CDR-SB). The CDR-SB is calculated as an average score, with lower scores indicating improvement. |
36 weeks
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]
時間枠:36 weeks
|
Incidence and severity of TEAEs |
36 weeks
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Global Program Lead、Actinogen Medical Ltd
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。